Navigation Links
TGen-Virginia G. Piper Cancer Center launches clinical trial for drug to treat lung cancer

SCOTTSDALE, Ariz. Sept. 21, 2011 Patients at Virginia G. Piper Cancer Center Clinical Trials are the first in the nation to participate in a clinical trial to determine the safety, tolerability and preliminary activity of an investigational drug that targets cell-signaling proteins associated with the most common form of lung cancer, as well as other forms of cancer such as lymphomas and neuroblastoma.

The first patient on the study was administered the first dose of AP26113 at Virginia G. Piper Cancer Center Clinical Trials, and the trial is now enrolling additional patients.

AP26113, discovered and being developed by ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA) of Cambridge, Mass., is a small molecule cancer therapy that targets the suppression of two oncogenes associated with non-small cell lung cancer (NSCLC): anaplastic lymphoma kinase (ALK), and epidermal growth factor receptor (EGFR). Oncogenes are those genes with the potential to cause cancer.

"AP26113 targets two oncogenes commonly cited in the lung cancer literature in recent years, ALK and EGFR," said Dr. Glen Weiss, the Principal Investigator for the clinical trial, a partnership of the Virginia G. Piper Cancer Center at Scottsdale Healthcare and the Translational Genomics Research Institute (TGen).

"We are the first site in the country to open a new clinical trial with AP26113, which has exciting possibilities," Dr. Weiss said of the Phase 1 and Phase 2 clinical trials planned for the drug. The Phase 1 study has just begun enrolling patients. By Phase 2, the study could include more than 100 patients at 11 clinical trial sites. "If AP26113 proves to be safe and effective, it could make a positive difference for patients with NSCLC and other cancers harboring ALK and EGFR abnormalities."

Dr. Weiss also is Director of Thoracic Oncology at Virginia G. Piper Cancer Center Clinical Trials, the partnership between TGen and Scottsdale Healthcare that treats cancer patients with promising new drugs.

And, Dr. Weiss is the new Chief Medical Officer of the Cancer Research and Biostatistics-Clinical Trials Consortium (CRAB-CTC), a Seattle-based cooperative research network, created by a group of preeminent lung cancer investigators. It represents more than 10 institutes worldwide dedicated to funding and facilitating clinical trials, thereby providing lung cancer patients with newly developed therapeutics as quickly as possible.

"Patients with advanced non-small cell lung cancer should ask their oncologists to have their tumors tested for EGFR mutation and ALK abnormalities. Identifying mutations or abnormalities in oncogenes associated with NSCLC can distinguish patients who are more likely to benefit from a targeted therapy," Dr. Weiss said. "NSCLC accounts for nearly 85 percent of all lung cancers. As many as 7 percent of NSCLC patients will have the abnormal ALK gene, and as many as 17 percent of patients with NSCLC in Western populations are EGFR positive."

AP26113 is a unique dual inhibitor of ALK and EGFR. In May, Pfizer filed its much-touted oncology agent crizotinib, a first-generation ALK inibitor, with regulators in the U.S. and Japan. On Aug. 26, through a fast-track process, the U.S. Food and Drug Administration approved crizotinib, to be sold as Xalkori. AP26113 is designed to overcome resistance to crizotinib and to an EGFR inhibitor called erlotinib, sold as Tarceva and made by OSI Pharmaceuticals Inc.


Contact: Steve Yozwiak
The Translational Genomics Research Institute

Related medicine news :

1. TGen, Virginia G. Piper Cancer Center studying new breast cancer drug
2. New Test Predicts Risk for Impotence After Prostate Cancer Therapy
3. Genes May Explain Blacks Bleaker Prostate Cancer Stats
4. The War on Cancer Continues
5. John Theurer Cancer Center among first clinical trial sites to join landmark MMRF study
6. MRI Can Spot Breast Cancer in High-Risk Women: Study
7. Higher Risk of Second Breast Cancer Seen in Black Women
8. 10 ways to make better decisions about cancer care
9. Costly blood clots more common than expected among cancer patients
10. Stem cells, potential source of cancer-fighting T cells
11. UNC scientist proves potential of new nanoparticle design for cancer therapy
Post Your Comments:
(Date:10/13/2015)... Houston, TEXAS (PRWEB) , ... October 13, 2015 ... ... firm and solution provider of IBM software products, introduced a new company, RightSensor™ ... sensor systems and data communications capability. RightSensor™ provides a fully-managed approach for ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... unique private messaging application, announced today a significant contract that will provide its ... Independence plans to build on the growing success of its Relay program, IBX ...
(Date:10/13/2015)... India (PRWEB) , ... October 13, 2015 , ... e-con ... camera solutions, today announced See3CAM_CU40, the industry’s first RGB-IR pixel format camera ... See3CAM_CU40, a new member of e-con’s See3CAM family of UVC USB 3.0 cameras, is ...
(Date:10/13/2015)... Nashville, Tenn. (PRWEB) , ... October 13, 2015 , ... ... life, and that’s why SmileCareClub , the leading remote invisible aligner system, has ... children who would otherwise go without it. For each aligner treatment plan purchased, SmileCareClub ...
(Date:10/13/2015)... ... ... Protein is essential to good health. You need it to make the ... protein does the average man need in order to stay healthy? , The ... of Harvard Men's Health Watch . Most Americans get about 15% of their ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... , October 13, 2015 ... World Thrombosis Day Interactive Infographic   --> ... World Thrombosis Day  to promote vital global awareness ... and symptoms. Thrombosis is the formation of potentially ... - resulting in venous thromboembolism (VTE) - or the ...
(Date:10/12/2015)... Given the intricacy of the anatomy and physiology of ... drug effectively to a specific ocular site. Several barriers have ... include dilution of a drug by tears, clearance of a ... issues with respect to the cornea, sclera and choroid. Approximately ... due to the aforementioned barriers. --> Given ...
(Date:10/12/2015)... 12, 2015  The Pharmacy Compounding Accreditation Board ... Pharmacy in Costa Mesa , ... the pharmacy,s commitment to meeting and/or exceeding national ... --> --> ... --> --> Harbor Compounding ...
Breaking Medicine Technology: